Crampton et al., 2004 - Google Patents
Sub-micrometer particle production by pressurized metered dose inhalersCrampton et al., 2004
- Document ID
- 17426130661517046017
- Author
- Crampton M
- Kinnersley R
- Ayres J
- Publication year
- Publication venue
- Journal of aerosol medicine
External Links
Snippet
Evidence from both the air pollution and inhaled aerosol therapy fields suggests that the physiological impact of fine and ultrafine aerosols (defined as those below 1000 and 100 nm aerodynamic diameter, respectively) may be greater than their mass or volume of active …
- 239000002245 particle 0 title abstract description 111
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230364015A1 (en) | Process for providing particles with reduced electrostatic charges | |
| De Boer et al. | Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique | |
| CA2693577C (en) | Dry-powder medicament | |
| Kwok et al. | Electrostatic charge characteristics of aerosols produced from metered dose inhalers | |
| CA2217047C (en) | Preparation of sodium chloride aerosol formulations | |
| Dolovich et al. | Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler | |
| JP2015508808A (en) | Inhalable pharmaceutical composition | |
| JP2004508899A (en) | Optimization of electrostatic dosing dry powder inhaler | |
| JP2016056202A (en) | Pharmaceutical composition for inhalation | |
| Kaviratna et al. | Evaluation of bio-relevant mouth-throat models for characterization of metered dose inhalers | |
| Rogers et al. | Determining equivalence of inhaled medications: Consensus statement from a workshop of the British association for lung research, held at royal brompton national heart & lung institute, london 24 june 1994 | |
| Crampton et al. | Sub-micrometer particle production by pressurized metered dose inhalers | |
| Farkas et al. | The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions | |
| Jókay et al. | Computer modeling of airway deposition distribution of Foster® NEXThaler® and Seretide® Diskus® dry powder combination drugs | |
| Hoe et al. | The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers | |
| Ball et al. | Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device | |
| Nadarassan et al. | Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor | |
| JP2004516046A (en) | Metered electric dose | |
| Stein et al. | The influence of electrostatic controls on MDI size distribution measurements | |
| Aloum et al. | Ex vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonide | |
| Zhu et al. | Design of a device for simultaneous particle size and electrostatic charge measurement of inhalation drugs | |
| Wauthoz et al. | Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation | |
| Singh et al. | Development and approval of inhaled respiratory drugs: a US regulatory science perspective | |
| Dorosz et al. | Dynamics of aerosol generation and flow during inhalation for improved in vitro-in vivo correlation (IVIVC) of pulmonary medicines | |
| Horváth et al. | Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients |